"Oxford Science Enterprises Co-Leads Seed Funding for AI-Powered Neurology Platform Kneu Health"

"Marriott Harrison advised Oxford Science Enterprises in co-leading the seed funding round for Kneu Health, a neurology platform that uses AI and smartphone-based monitoring to improve diagnosis and treatment of Parkinson’s and dementia. By analyzing speech, movement, and cognition, Kneu Health provides predictive biomarkers to help neurologists focus on patients who need the most care, addressing the challenges of increasing cases and limited healthcare resources."

Marriott Harrison advised Oxford Science Enterprises (OSE) in co-leading the seed funding round for Kneu Health, a neurology platform utilising AI and smartphone interactions. The transaction involved seed funding for Kneu Health, which aims to address delays in Parkinson’s and dementia diagnosis and treatment caused by hospital wait times and a shortage of neurologists. Kneu Health’s platform integrates smartphone-based monitoring and clinically trained AI to analyse speech, movement, and cognition, generating predictive biomarkers for clinicians to monitor patients. This technology helps neurologists focus on patients who need the most care, reducing unnecessary appointments and improving treatment outcomes. The Marriott Harrison team included VC Partner Bradley Heath and Associate Sean Kelly.

"Oxford Science Enterprises Co-Leads Seed Funding for AI-Powered Neurology Platform Kneu Health"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads